Spruce Biosciences, Inc. (SPRB)
| Market Cap | 362.81M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.54M |
| Shares Out | 23.30M |
| EPS (ttm) | -4.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $15.41 |
| Previous Close | $15.58 |
| Change ($) | -0.17 |
| Change (%) | -1.09% |
| Day's Open | 15.57 |
| Day's Range | 15.28 - 16.00 |
| Day's Volume | 91,450 |
| 52-Week Range | 14.18 - 35.60 |
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #ENDO2021--Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society's 2021 Annual Mtg
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Announce Phase 1 and 2 Data of Tildacerfont at Endocrine Society's 2021 Annual Meeting
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Participate in Upcoming Investor Conferences
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs ...
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week
Shares of Spruce Biosciences Inc. rallied in their public debut, as they opened 21% above the initial public offering price. The stock's first trade was at $18.14 at 11:37 a.m.
Spruce Biosciences Inc. said Friday that its initial public offering, which was upsized by 20%, priced at $15 a share, as the California-based biopharmaceutical company developing treatments for endocri...
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Announces Pricing of Upsized Initial Public Offering
About SPRB
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b c... [Read more...]
| Industry Biotechnology | IPO Date Oct 9, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol SPRB |
Analyst Forecasts
According to 4 analysts, the average rating for SPRB stock is "Buy." The 12-month stock price forecast is 33.25, which is an increase of 115.77% from the latest price.